Kornimate/medical-research-clean huggingface dataset:
botulinum toxin type a block of the sphenopalatine ganglion in chronic rhinosinusitis with nasal polyposis

Conditions: Chronic Disease; Nasal Polyposis; Rhinitis

Summary: chronic rhinosinusitis (crs) with nasal polyps is a particularly challenging form of chronic rhinosinusitis in several ways. patients have significantly more severe symptom burden and worse quality of life than patients with chronic rhinosinusitis without nasal polyps. many patients return to the health care providers with persistent symptoms after repeated medical and surgical treatment. patients have usually tried several different types of treatments, ranging from less invasive procedures to extensive surgical treatment. the surgical treatment is often repeated several times. the most common surgical treatment is functional endoscopic sinus surgery, another established procedure is vidian neurectomy. the main object of this pilot study is to investigate the safety of onabotulinumtoxin a towards the sphenopalatine ganglion (spg) in crs patients with nasal polyps. efficacy data will also be collected to provide indication on whether future placebo-controlled studies should be performed. onabotulinumtoxin a inhibits the secretion of acetylcholine, blocking the parasympathetic reflex cascade in the spg. as a result, the investigators expect less mucosal swelling, secretion and nasal polyps. the duration of such a blockade is believed to last for 3-9 months and will not lead to damage of the nerve. this study opens up for improved treatment with less complications.


Eligibility criteria:
inclusion criteria: * written informed consent * chronic rhinosinusitis with nose polyps (crswnp) according to european position paper on rhinosinusitis and nasal polyps (epos) criteria * no satisfactory effect of medicinal or surgical treatment exclusion criteria: * systemic or local disease or condition that may result in a higher risk for complications * psychiatric disorder that is indicates against the treatment * pregnancy, breastfeeding, fertile female not using contraception * abuse of drugs, narcotics or alcohol * hypersensitivity against marcain, lidocain, xylocain, or adrenalin, and similar drugs * anatomical conditions that hinder injection * known sensitivity for botulinum toxin type a or for adjuvant substances * treatment with drugs that interact with botulinum toxin type a: * suspicion of polyps caused by an allergy * suspicion of samters triade

Keywords: botulinum toxin type a block sphenopalatine ganglion
capthpv : validation of the method "capthpv" for the diagnosis of human papillomavirus associated infiltrating carcinomas

Conditions: Cervical Cancer; Vulvar Cancer; Anal Cancer; Oropharynx Cancer; Oral Cavity Cancer; Penis Cancer

Summary: the current project is based on the assumption that a diagnosis of human papillomavirus associated infiltrating carcinomas can be made from a blood sample for patient with cervical cancer, vulvar cancer, anal cancer, oropharynx cancer, oral cavity cancer or penis cancer at any stage of the disease and including surgical treatment for the small tumors.


Eligibility criteria:
inclusion criteria: * age \>18 years * patient with cervical cancer, vulvar cancer, anal cancer, oropharynx cancer, oral cavity cancer or penis cancer * patient naive of any treatment for this pathology * patient capable and willing to follow all procedures of the study in accordance with the study * ability to provide an informed written consent form * affiliation to a social security system exclusion criteria: * patients who have already undergone surgical treatment leading to complete removal of the lesions or who have started treatment with radiotherapy and / or chemotherapy * patient whose health status contraindicates a blood sample of 20 ml, * absence of informed written consent form * pregnant or breast feeding females * patients deprived of liberty or under supervision

Keywords: hpv infection blood sample biopsy
the effects of progressive muscle relaxation training in women with fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of the study is to examine the effects of progressive muscle relaxation training given in addition to a combined exercise program in women with fibromyalgia.

fibromyalgia syndrome is a complex, non-inflammatory pain syndrome characterized by whole-body pain, pain at specific tender points, fatigue, and sleep disturbance the prevalence of fibromyalgia in the world population varies between 0.2% and 6.4%, and it more frequently affects middle-aged women (30-50 years old). the etiology of fibromyalgia is not fully known. there are no generally accepted objective clinical findings, radiographic abnormalities, or laboratory tests to assess the presence of fibromyalgia and measure fibromyalgia severity. therefore, questionnaires measuring patients' subjective responses remain important in the evaluation of fibromyalgia patients until now. current treatment recommendations for fibromyalgia strongly support a multifaceted regimen, including patient education, physical therapy, massage, cognitive behavioral therapy, specific pharmacotherapy, restorative sleep, and exercise. exercise includes aerobic exercise, strengthening and stretching. progressive muscle relaxation therapy is an alternative complementary therapy based on the principle of progressive tensing and relaxing of major body muscles to relieve psychological tension. the therapy has no time or space restrictions and does not require any special equipment.

Eligibility criteria:
inclusion criteria: * women diagnosed with fibromyalgia over the age of 20 * volunteering to participate in the study. exclusion criteria: * neurological, infectious, endocrine and/or other inflammatory rheumatic diseases * serious psychiatric illness (schizophrenia, etc.) * any condition that prevents exercise (advanced heart, respiratory or orthopedic problems) * malignancy * pregnancy * menopause * participating in a physical therapy program (receiving exercise / relaxation training) in the last 6 months

Keywords: fibromyalgia progressive muscle relaxation combined exercise rehabilitation
study evaluating dvs-233 sr in adult outpatients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: primary objective: to compare the antidepressant efficacy and safety of subjects receiving dvs-233 sr versus subjects receiving placebo. secondary objective: to assess the response of subjects receiving dvs-233 sr for the clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms (hamilton psychiatric rating scale for depression, 17-item \[ham-d17\] less than or equal to 7) versus those subjects receiving placebo.


Eligibility criteria:
inclusion criteria: * outpatients * sexually active women participating in the study must use a medically acceptable form of contraception * subjects must have a primary diagnosis of major depressive disorder of 4 on clinical global impressions-severity scale (cgi-s) exclusion criteria: * treatment with dvs-233 sr at any time in the past * treatment with venlafaxine (immediate release \[ir\] or extended release \[er\]) within 90 days of study day 1 * known hypersensitivity to venlafaxine (ir or er)
evaluation of clearllab ls screening panel

Conditions: Hematologic Malignancy; Hematologic Neoplasms; Hematologic Diseases

Summary: this is a multi-center study to evaluate the clinical performance of clearllab ls screening panel with specimens from subjects for the diagnosis of hematologic malignancies.

this study aims to evaluate the clinical accuracy of clearllab ls screening panel in the diagnosis of hematologic malignancies. the residual specimens, which from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematologic diseases work-up, will be tested by clearllab ls screening panel. clearllab ls screening panel is ce-ivd marked immunophenotyping reagents under the european union (eu) regulation, and this study is aimed to validate its clinical performance in chinese population.

Eligibility criteria:
inclusion criteria: * residual whole blood, bone marrow, or lymph node tissue samples from subjects with hematologic tumor-related symptoms and/or signs that are clinically recommended for flow cytometry immunophenotyping exclusion criteria: * specimens and/or spent samples that are visibly hemolyzed * specimens and/or spent samples that are visibly clotted * specimens and/or spent samples collected in ethylene diamine tetraacetic acid (edta) anticoagulant older than 24 hours from time of collection * specimens and/or spent samples collected in heparin or acid citrate-dextrose (acd) anticoagulant older than 48 hours from time of collection * samples with insufficient volume to complete the protocol tests * samples from subjects with known myeloid malignancies or multiple myeloma
the effect on knee joint loads of analgesic use compared with exercise in patients with knee osteoarthritis - an rct

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to compare the effects of neuromuscular exercise and analgesic use on knee joint load, in patients with mild to moderate knee osteoarthritis (oa). it is expected that the two groups will receive equipotent pain relieving effect, despite this, the investigators expect a between group difference in knee joint load, and the exercise group will have a reduction in knee joint load.


Eligibility criteria:
inclusion criteria: * compliance with the acr criteria * medial knee oa defined as "no osteoarthritis", "doubtful narrowing of joint space and/or possible osteophytes", "definite osteophytes and possible narrowing of joint space", "multiple osteophytes, definite narrowing of joint space and some sclerosis and deformity of bone ends". this corresponds to the kellgren and lawrence (kl) grades 0, 1, 2 and 3 respectively * willingness to participate in exercise and use of analgesics * a maximum of 75/100 points in the koos pain subscale * bmi of 32 or less exclusion criteria: * medial greater than lateral joint space width * medial knee oa of kl grade 4 * knee surgery or steroid injection within the past 6 months * already taking max dose nsaids or acetaminophen * any physician-determined condition that is a contraindication for use of acetaminophen, nsaids or to exercise * problems affecting the lower extremity overriding the problems from the knee * knee surgery planned in the next 6 months * known acl tear within the past 6 months * acl reconstruction * diagnosis of systemic arthritis * difficulty complying with treatment schedule * inability to fill out questionnaires * inability to ambulate without an assistive device * ankle, knee or hip replacement * tibial/femoral osteotomy

Keywords: exercise therapy gait joint load knee joint middle aged osteoarthritis, knee/therapy pain management
catch-up intervention in increasing cancer screening and prevention care in uninsured patients at community health centers

Conditions: Breast Carcinoma; Cervical Carcinoma; Colorectal Carcinoma; Health Status Unknown; Human Papillomavirus Infection; Malignant Neoplasm

Summary: this randomized research trial studies the community-based health information technology (hit) tools for cancer screening and health insurance promotion (catch-up) intervention in increasing cancer screening and prevention care in uninsured patients at community health centers. the catch-up intervention may contribute to increased rates of insurance coverage, leading to improved cancer screening and prevention rates in community health care settings, and general recommended preventive care.

primary objectives: i. evaluate the effect of the catch-up intervention on up-to-date status of cancer screening and preventive care received by patients. ii. evaluate the effect of the catch-up intervention on patients? insurance coverage rates. iii. evaluate the intervention implementation process, patient and community health center (chc) staff acceptance and use of the catch-up tools, and the patient-, provider-, and system-level factors associated with successful implementation and sustainability of the tools, using mixed methods. outline: chc clinics are randomized to 1 of 2 groups. we compare between groups and with a matched-comparison group. group i (intervention arm 1): participants receive catch-up tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline. group ii (intervention arm 2): participants receive catch-up tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation. matched-comparison group: a clinic-level matched comparison group will be derived from the ochin membership by using propensity score matching techniques. comparison group clinics will not participate actively in any study activities but, as part of their member business associate agreement with ochin, have already agreed to provide data through ochin for pre- and post-implementation analysis in the study.

Eligibility criteria:
inclusion criteria: * established patients at chc sites * low-income * ethnically diverse populations with lower rates of cancer screening compared to national rates * uninsured patients * patients 18 to 64 years of age * clinics must be primary care sites, with greater than 1,000 adult patients in the past year, be located in a state that expanded medicaid, and have implemented the ochin ehr prior to january 1, 2012

Keywords: insurance coverage insurance continuity
pillcam™ colon capsule endoscopy (pcce) in the visualization of the colon

Conditions: Colonic Diseases

Summary: to see if pillcam colon will demonstrate diagnostic yield \>80% in detecting significant colonic pathologies when compared to colonoscopy in the target population.

the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. this is expected to improve the capability of the given® diagnostic system to detect colonic pathologies and to serve as a diagnostic and screening tool for colonic disease. this study is designed to compare capsule colonoscopy and colonoscopy procedures in detecting colon abnormalities. note that the physician performing the capsule endoscopy and reading the capsule videos and the physician performing the colonoscopy were unaware of each other's findings until completion of the examinations and reports (assessor-blind).

Eligibility criteria:
inclusion criteria: * subject was referred for colonoscopy for one of the following reasons: * subjects over ≥ 50 years of age with one or more of the following clinical symptoms: rectal bleeding, hematochezia, melena, positive fecal occoult blood test (fobt), recent change of bowel habits, or diarrhea/constipation of recent onset. * any subject ≥ 18 years of age with: * positive findings in the colon on a gastrointestinal (gi) radiographic study * personal history of colorectal cancer (crc) or adenomatous colonic polyps and at least 3 years since last colonoscopy * suspected or known ulcerative colitis exclusion criteria: * subject has dysphagia * subject has congestive heart failure * subject has renal insufficiency * subject is known or is suspected to suffer from intestinal obstruction. * chronic use of laxatives * subject has a cardiac pacemakers or other implanted electro medical devices. * women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception. * subject is expected to undergo mri examination within 7 days after ingestion of the capsule. * subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator. * subject has any condition, which precludes compliance with study and/or device instructions. * age \< 18 years * subject suffers from life threatening conditions * subject is currently participating in another clinical study * subject has known slow gastric emptying time

Keywords: suspected colonic disease known colonic disease
impact of excision margins on survival and recurrence rate in patients with thick melanoma (>2mm)

Conditions: Melanoma

Summary: objective: to investigated the impact of the excision of melanoma 2mm≤ in thickness with 1cm surgical margins on survival of the patients compared with 2 cm surgical margins. background: early recognition and appropriate excision play a crucial role in management of malignant melanoma, while the size of surrounding normal skin that should be excised is area of controversies. methods: the investigators will conduct a retrospective population-based survey in patients with primary melanoma 2 mm≤ in thickness undergoing tumor excision with 1 cm and 2 cm margins in the investigators center. for both groups, the patients' charts reviewed for data including patient gender, age, tumor location, tumor type, clark's level, breslow thickness, tumor type, presence of ulceration, findings of sentinel nodes, local recurrences, locoregional metastases, disease free survival and overall survival were calculated for both groups.

background early recognition and appropriate excision play a crucial role in management of malignant melanoma, while the size of surrounding normal skin that should be excised is area of controversies. objective to investigated the impact of the excision of melanoma 2mm≤ in thickness with 1cm surgical margins on survival of the patients compared with 2 cm surgical margins. methods the investigators will conduct a retrospective population-based survey in patients with primary melanoma 2 mm≤ in thickness undergoing tumor excision with 1 cm and 2 cm margins in the investigators center. for both groups, the patients' charts reviewed for data including patient gender, age, tumor location, tumor type, clark's level, breslow thickness, tumor type, presence of ulceration, findings of sentinel nodes, local recurrences, locoregional metastases, disease free survival and overall survival were calculated for both groups.

Eligibility criteria:
inclusion criteria: * histologically confirmed melanoma * safety margin 1 cm or 2 cm * tumor thickness according to breslow \>2mm exclusion criteria * safety margin less 1 cm * unclear safety margins

Keywords: margin of safety
oxycodone vs. fentanyl in early postoperative pain after total hip replacement

Conditions: Pain, Postoperative

Summary: oxycodone is one of the most widely used opioids for pain treatment. many studies demonstrated good efficacy of oxycodone on postoperative pain. in this study, we assess the efficacy and side effects of bolus intravenous of oxycodone injection compared to those of fentanyl in patients after total hip replacement surgery.

oxycodone is one of the most widely used opioids for pain treatment. there have been several studies on the efficacy and side effects of oxycodone. oxycodone has been known to have the same potency with morphine. many studies demonstrated good efficacy of oxycodone on postoperative pain. in this study, we designed a prospective, randomized, and double-blind study to assess the efficacy and side effects of bolus intravenous of oxycodone injection compared to those of fentanyl in patients who underwent the total hip replacement surgery.

Eligibility criteria:
inclusion criteria: * 19-65 years of age * asa physical status classification i or ii * scheduled for total hip replacement surgery exclusion criteria: * allergic to study drugs * patient with asthma or copd, patient who is severely respiratory depressed * renal of hepatic insufficiency * epileptic status * intracranial lesion associated with increased intracranial pressure * acute abdomen, patient who has diagnosed paralytic ileus or suspicious ileus * pregnant or lactating women

Keywords: postoperative pain
the risk of hypertension associated with oral glucocorticoids in chronic inflammatory diseases

Conditions: Hypertension

Summary: glucocorticoids are widely used for the treatment of chronic inflammatory diseases. in 2008, it was estimated that 0.8% of the united kingdom adult population had used long-term (≥ 3 months) glucocorticoids, rising to 3% in women aged over 80 years. the aim of the project is to investigate the dose-response estimates of risk of high blood pressure associated with oral glucocorticoids.

hypertension is a chronic condition which affects 1 in 5 of the world adult population. the cause of hypertension is unknown in about 95% of patients, whilst 5% are secondary to underlying adrenal disorders or other identifiable causes. glucocorticoids are widely used for the treatment of chronic inflammatory diseases. in 2008, it was estimated that 0.8% of the uk adult population had used long-term (≥ 3 months) glucocorticoids, rising to 3% in women aged over 80 years. glucocorticoids are effective in controlling underlying chronic inflammatory disease in majority of cases. however, their continuous use can result in a variety of complications, including hypertension.although it is acknowledged that excess cortisol is a leading cause of hypertension, the role of exogenous glucocorticoids is less known. the aim of the project is to investigate the dose-response estimates of risk of high blood pressure associated with oral glucocorticoids. this is a retrospective cohort study of people diagnosed with at least one of six chronic inflammatory diseases (polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, vasculitis and inflammatory bowel disease). this study will be based on the analysis of existing primary care health records routinely collected, linked to hospital and mortality data.

Eligibility criteria:
inclusion criteria: * patients aged 18 years old or over * registered in a participating general practice 1 year or more during the study period * minimum of 1 year prior to study entry meeting cprd data quality * diagnosed with at least one of the 6 chronic inflammatory diseases exclusion criteria: * patients aged under 18 years during the study period * registered in general practices that did not consent to data linkage